A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

Unknown

(2014) Petros Grivas et al.   MOLECULAR MEDICINE

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

Genome-wide association study identifies multiple loci associated with bladder cancer risk

(2013) Jonine D. Figueroa et al.   HUMAN MOLECULAR GENETICS

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

(2013) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

CD10 and E-Cad Expression in Urinary Bladder Urothelial and Squamous Cell Carcinoma

(2013) Ola M. Omran   JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

(2013) Jeffrey S Ross et al.   MODERN PATHOLOGY

Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation

(2013) Guangwu Guo et al.   NATURE GENETICS

Frequent truncating mutations of STAG2 in bladder cancer

(2013) David A Solomon et al.   NATURE GENETICS

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

(2012) F. Petrelli et al.   ANNALS OF ONCOLOGY

Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma

(2012) Yu-Ning Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune expression of E-cadherin and α, β and γ-Catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas

(2012) Sabrina Thalita dos Reis et al.   International Braz J Urol

EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells

(2011) Magdalena M. Grabowska et al.   CELLULAR SIGNALLING

Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin

(2011) Jian-Hong Zuo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75

(2011) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

(2010) Lucie C. Kompier et al.   PLoS One

Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection

(2010) Mototsugu Muramaki et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

(2009) G. K. Philips et al.   ANNALS OF ONCOLOGY

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

(2009) Daniel P. Petrylak et al.   BJU INTERNATIONAL

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

(2009) Christian Wülfing et al.   CANCER

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

(2008) P. C. Black et al.   CLINICAL CANCER RESEARCH

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE